Oral

U.S. Oral Surgery Management Continues Phenomenal Growth

Retrieved on: 
Tuesday, September 19, 2023
Facial, Popper, DRS, OMS, Hall, Oral, Growth, MSO, Oral and maxillofacial surgery, Dental implant, Dentistry

Oral Surgery Management (USOSM) is announcing three partnerships with oral and maxillofacial surgery practices in two states.

Key Points: 
  • Oral Surgery Management (USOSM) is announcing three partnerships with oral and maxillofacial surgery practices in two states.
  • Fried & Popper of Mayfield Heights, Ohio; and Mill Creek Oral & Maxillofacial Surgery Associates, which has offices in Boardman and Austintown, Ohio.
  • The first company of its kind, USOSM continues to be the leader in the MSO space with more than 180 oral and maxillofacial surgery (OMS) practice locations across 26 states.
  • Fried & Popper and Mill Creek Oral & Maxillofacial Surgery Associates.”

Exactech Expands Vantage® Ankle Portfolio with Clearance of Advanced Activit-E™ Polyethylene

Retrieved on: 
Thursday, September 21, 2023
Medical Devices, Surgery, Medical Supplies, Hospitals, Clinical Trials, Other Health, Biotechnology, Physical Therapy, General Health, Health, American Orthopaedic Foot and Ankle Society, Vitamin E, Polyethylene, Multimedia, Patient, Ankle replacement, Foot, Fracture, Oral, Massachusetts General Hospital, Engineering, Ankle

Exactech , a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced 510(k) clearance for its Activit-E™ polyethylene for the Vantage® Total Ankle System.

Key Points: 
  • Exactech , a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced 510(k) clearance for its Activit-E™ polyethylene for the Vantage® Total Ankle System.
  • This announcement comes on the heels of the Activit-E clearance for the Truliant® Knee System , which was announced last month.
  • View the full release here: https://www.businesswire.com/news/home/20230921355156/en/
    Exactech Receives FDA Clearance for Activit-E Polyethylene for Ankle Replacement.
  • (Photo: Business Wire)
    “We’re excited to bring Activit-E to the ankle portfolio.

Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference

Retrieved on: 
Sunday, September 17, 2023
Biotechnology, COVID-19, Health, Pharmaceutical, Clinical Trials, Viral, Medication, European Scientific Cooperative on Phytotherapy, Oral, Correlation, RSV, Palacio de Congresos, Conference, Treatment, Vaccine, Pharmaceutical industry

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 9th European Scientific Working Group on Influenza (ESWI) Influenza Conference on September 17-20, 2023 at the Palacio de Congresos de Valencia in Valencia, Spain.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 9th European Scientific Working Group on Influenza (ESWI) Influenza Conference on September 17-20, 2023 at the Palacio de Congresos de Valencia in Valencia, Spain.
  • Poster Title: “EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results from a Phase 1 Study in Healthy Subjects and Correlation with In Vitro Antiviral Activity”

U.S. Oral Surgery Management Making Strides on West Coast

Retrieved on: 
Tuesday, September 12, 2023
Oral, MSO, Health, Oral and maxillofacial surgery, OMS, Dentistry

Oral Surgery Management (USOSM) is announcing three partnerships with oral and maxillofacial surgery practices in California and Washington state.

Key Points: 
  • Oral Surgery Management (USOSM) is announcing three partnerships with oral and maxillofacial surgery practices in California and Washington state.
  • They include Whittier Oral and Maxillofacial Surgery of Whittier, California; North Cascade Implant Oral Surgery Center of Mount Vernon, Washington; and Oral & Facial Surgery Centers of Washington, which has locations in Puyallup and Tacoma.
  • Founded in November 2017, USOSM is a specialty management services organization (MSO) that exclusively serves premier, board certified oral and maxillofacial surgeons.
  • “We’re excited to announce partnerships with Whittier Oral and Maxillofacial Surgery, North Cascade Implant Oral Surgery Center and Oral & Facial Surgery Centers of Washington.

Blue Earth Therapeutics Announces Promising Results of Preclinical Evaluation of 225Ac-rhPSMA-10.1 for Potential Targeted Alpha Therapy of Prostate Cancer

Retrieved on: 
Monday, September 11, 2023
Research, Clinical Trials, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Radioactive decay, PSMA, PET, Nuclear medicine, Trial of the century, Annual general meeting, Oral, European Association of Urology, Therapy, IND, Prostate cancer, Medical imaging

Results showed that both 225Ac-rhPSMA-10.1 and 177Lu-rhPSMA-10.1 demonstrated excellent PSMA binding affinity, high cellular internalization and similar lipophilicity.

Key Points: 
  • Results showed that both 225Ac-rhPSMA-10.1 and 177Lu-rhPSMA-10.1 demonstrated excellent PSMA binding affinity, high cellular internalization and similar lipophilicity.
  • Therapeutic response and efficacy were evaluated in a preclinical prostate cancer model which showed that 225Ac-rhPSMA-10.1 significantly suppressed tumor growth relative to control.
  • 225Ac-rhPSMA-10.1 is an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, and the lead alpha-emitting candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals.
  • IND-enabling studies have been completed and we plan to initiate a Phase 1 clinical study of 225Ac-rhPSMA-10.1 in the first half of 2024.”

SKINCEUTICALS ANNOUNCES OPENING OF SKINCEUTICALS SKINLAB™ WINTER PARK IN ORLANDO

Retrieved on: 
Tuesday, September 12, 2023
Neurotoxin, Partnership, Senior, Village, 3D, Oral and maxillofacial surgery, Skin, Ageing, Statistics, Acne, Laser, Patient, Physician, Oral, Growth, Filler (linguistics), Skinlab, ARPM, Winter Park Village, Population growth, Cosmetics, Pharmaceutical industry, Central Florida

NEW YORK, Sept. 12, 2023 /PRNewswire/ -- SkinCeuticals, the #1 medical aesthetic skincare brand worldwide1, announces the opening of the brand's eleventh SkinLab location, SkinCeuticals SkinLab™ Winter Park, in the bustling Winter Park Village in the heart of Orlando, Florida. This new location features brand partners Dr. Jeffrey Hartog, dual Board-Certified Plastic, Oral and Maxillofacial Surgeon, as well as managing partners, Michelle Hartog, ARPN, and Elizabeth Pain, ARPM, to fully own and operate SkinCeuticals SkinLab™ Winter Park. As the latest addition to the SkinCeuticals SkinLab™ network, this expansion joins existing locations including St. Helena, CA; Stamford, CT; Houston, TX; Charleston, SC; Palm Desert, CA; Grand Rapids, MI; Scottsdale, AZ; Miami, FL; Santa Monica, CA; and New York, NY.

Key Points: 
  • NEW YORK, Sept. 12, 2023 /PRNewswire/ -- SkinCeuticals, the #1 medical aesthetic skincare brand worldwide1, announces the opening of the brand's eleventh SkinLab location, SkinCeuticals SkinLab™ Winter Park, in the bustling Winter Park Village in the heart of Orlando, Florida.
  • SkinCeuticals SkinLab™ Winter Park will be the brand's second largest location in the country and combines professional treatments with SkinCeuticals gold-standard-at-home skincare for the ultimate integrated skincare destination.
  • With such substantial growth, SkinCeuticals SkinLab™ Winter Park will provide integrated skincare solutions and establish a strong presence in a thriving region.
  • The SkinCeuticals SkinLab™ Winter Park will welcome visitors beginning August 2023.

ACE SOUTHERN Announces Strategic Supply Partnership with U.S. Oral Surgery Management

Retrieved on: 
Thursday, August 31, 2023
Foam, Partnership, Surgeon, Public sector banks in India, Plasma protein binding, GM, Patient, ACE, Oral and maxillofacial surgery, Oral, American Association of Tissue Banks, Dentistry, Pharmaceutical industry

WEST COLUMBIA, S.C., Aug. 31, 2023 /PRNewswire/ -- ACE SOUTHERN, a leading global provider of Oral Surgery and biomaterial products, and U.S. Oral Surgery Management, a specialty management service company that exclusively serves premier oral and maxillofacial surgeons, are excited to announce a multi-year, first in the industry, comprehensive partnership for Oral Surgery solutions, effective immediately.

Key Points: 
  • WEST COLUMBIA, S.C., Aug. 31, 2023 /PRNewswire/ -- ACE SOUTHERN, a leading global provider of Oral Surgery and biomaterial products, and U.S.
  • Oral Surgery Management, a specialty management service company that exclusively serves premier oral and maxillofacial surgeons, are excited to announce a multi-year, first in the industry, comprehensive partnership for Oral Surgery solutions, effective immediately.
  • ACE SOUTHERN Announces Strategic Supply Partnership with U.S.
  • Oral Surgery Management
    As part of the partnership, ACE SOUTHERN will support USOSM offices with a broad range of surgical supplies, pharmaceuticals, bone grafting, and membrane solutions.

Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium

Retrieved on: 
Monday, August 28, 2023
Interim, Diabetes, Safety, DR, Titles of distinction awarded by the University of Oxford, DRSS, Diabetic retinopathy, Paratriathlon, OCUP, Patient, Oral, FDA, Woman, Treatment, Disease, Pharmaceutical industry, Ophthalmology

The presentation “ZETA-1 Phase 2 Trial Safety and Tolerability Results for APX3330: A Novel, Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy” was delivered by Priya Vakharia M.D., vitreo-retina specialist at Retina Vitreous Associates of Florida.

Key Points: 
  • The presentation “ZETA-1 Phase 2 Trial Safety and Tolerability Results for APX3330: A Novel, Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy” was delivered by Priya Vakharia M.D., vitreo-retina specialist at Retina Vitreous Associates of Florida.
  • The abstract received the Joanne Angle Abstract of Distinction Award out of nearly 600 submissions.
  • “I am honored to receive the prestigious Joanne Angle Abstract of Distinction award from WIO for this abstract on ZETA-1 data, and to have the opportunity to share these important data with my fellow ophthalmologists,” said Priya Vakharia M.D.
  • If approved, APX3330 can allow us to intervene early in the disease and prevent vision-threatening complications.”
    Rick Rodgers, Interim CEO of Ocuphire added.

New Enhancements and Advancements in the Companion Animal Ear Infection Treatment Market 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 23, 2023
Pharmaceutical, Health, Veterinary, Cats and Dogs, Pressure, High, Research report, Block cipher mode of operation, Labyrinthitis, Dog, COVID-19, Consumer, Research, USD, Cat, Certification, Compound annual growth rate, Otitis externa, Social impact assessment, Investment, Quinolone antibiotic, Oral, R, Vaccine, Pharmaceutical industry, Pet industry, Topical medication, Aminoglycoside, Otitis media

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Companion Animal Ear Infection Treatment Market.

Key Points: 
  • The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Companion Animal Ear Infection Treatment Market.
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Companion Animal Ear Infection Treatment Market?
  • What is the market share of the leading vendors in the Global Companion Animal Ear Infection Treatment Market?
  • What modes and strategic moves are considered suitable for entering the Global Companion Animal Ear Infection Treatment Market?

Abra Health Expands Dental Services with Acquisition of Two Prominent Oral Surgery Practices in Northern New Jersey

Retrieved on: 
Wednesday, August 2, 2023
General Health, Health, Dental, Practice Management, Extraction (chemistry), Patient satisfaction, Dental implant, Multimedia, Name, Acquisition, DMD, Patient, DDS, Oral and maxillofacial surgery, Dental care, Oral, Dentistry

Abra Health, a leading provider of comprehensive dental care, is excited to announce the acquisition of two oral surgery practices in the Northern New Jersey area.

Key Points: 
  • Abra Health, a leading provider of comprehensive dental care, is excited to announce the acquisition of two oral surgery practices in the Northern New Jersey area.
  • The practices, known as Bayonne Oral Surgery in Bayonne, NJ, and Oral & Maxillofacial Surgery Institute in Newark, NJ, will join forces under the new umbrella of the Abra Health group called Garden State Oral Surgery Group.
  • "We are thrilled to welcome Bayonne Oral Surgery and Oral & Maxillofacial Surgery Institute to the Abra Health family," said Dr. Michael Skolnick, DMD, CEO of Abra Health.
  • For more information about Garden State Oral Surgery Group and the expanded dental services now available, please visit the new website at gardenstateos.com.